These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19450154)

  • 1. Metabolic syndrome in a workplace: prevalence, co-morbidities, and economic impact.
    Schultz AB; Edington DW
    Metab Syndr Relat Disord; 2009 Oct; 7(5):459-68. PubMed ID: 19450154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the association between metabolic syndrome and disease in a workplace population over time.
    Schultz AB; Edington DW
    Value Health; 2010; 13(2):258-64. PubMed ID: 19818063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.
    Lamb CE; Ratner PH; Johnson CE; Ambegaonkar AJ; Joshi AV; Day D; Sampson N; Eng B
    Curr Med Res Opin; 2006 Jun; 22(6):1203-10. PubMed ID: 16846553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between changes in metabolic syndrome and changes in cost in a workplace population.
    Schultz AB; Edington DW
    J Occup Environ Med; 2009 Jul; 51(7):771-9. PubMed ID: 19528830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm.
    Kessler RC; Lane M; Stang PE; Van Brunt DL
    Psychol Med; 2009 Jan; 39(1):137-47. PubMed ID: 18423074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The medical cost of cardiometabolic risk factor clusters in the United States.
    Sullivan PW; Ghushchyan V; Wyatt HR; Hill JO
    Obesity (Silver Spring); 2007 Dec; 15(12):3150-8. PubMed ID: 18198326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impairment in work productivity and health-related quality of life in patients with IBS.
    Dean BB; Aguilar D; Barghout V; Kahler KH; Frech F; Groves D; Ofman JJ
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S17-26. PubMed ID: 15926760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of self-reported employee physical activity with metabolic syndrome, health care costs, absenteeism, and presenteeism.
    Burton WN; Chen CY; Li X; Schultz AB; Abrahamsson H
    J Occup Environ Med; 2014 Sep; 56(9):919-26. PubMed ID: 25153302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care utilization and costs by metabolic syndrome risk factors.
    Boudreau DM; Malone DC; Raebel MA; Fishman PA; Nichols GA; Feldstein AC; Boscoe AN; Ben-Joseph RH; Magid DJ; Okamoto LJ
    Metab Syndr Relat Disord; 2009 Aug; 7(4):305-14. PubMed ID: 19558267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and disability costs of depressive illness in a major U.S. corporation.
    Druss BG; Rosenheck RA; Sledge WH
    Am J Psychiatry; 2000 Aug; 157(8):1274-8. PubMed ID: 10910790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes.
    Jacob-Tacken KH; Koopmanschap MA; Meerding WJ; Severens JL
    Health Econ; 2005 May; 14(5):435-43. PubMed ID: 15497201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical and productivity costs of anxiety disorders: case control study.
    Marciniak M; Lage MJ; Landbloom RP; Dunayevich E; Bowman L
    Depress Anxiety; 2004; 19(2):112-20. PubMed ID: 15022146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial impact of a comprehensive multisite workplace health promotion program.
    Aldana SG; Merrill RM; Price K; Hardy A; Hager R
    Prev Med; 2005 Feb; 40(2):131-7. PubMed ID: 15533521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Employee Sleep With Workplace Health and Economic Outcomes.
    Burton WN; Chen CY; Schultz AB; Li X
    J Occup Environ Med; 2017 Feb; 59(2):177-183. PubMed ID: 28166124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Workplace health promotion programs. An overview.
    Pencak M
    Nurs Clin North Am; 1991 Mar; 26(1):233-40. PubMed ID: 2000322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a musculoskeletal disability management program on medical costs and productivity in a large manufacturing company.
    Bunn WB; Baver RS; Ehni TK; Stowers AD; Taylor DD; Holloway AM; Duong D; Pikelny DB; Sotolongo D
    Am J Manag Care; 2006 Dec; 12 Spec no.():SP27-32. PubMed ID: 17173488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.